Literature DB >> 10537783

Evidence-based medicine, utilities, and quality of life.

M M Brown1, G C Brown, S Sharma, S Garrett.   

Abstract

Evidence-based medicine provides the highest quality of information for medical practitioners. At the top of the pyramid of evidence-based medicine are the prospective, randomized clinical trials and meta-analysis. Evidence-based medicine can be incorporated with quality-of-life parameters; the latter can be quantified using utility theory. With utility theory, utility values range from 0.0 (death state) to 1.0 (perfect health state). The higher the utility value, the better a person's quality of life. Interventional treatment can change the utility level experienced by a patient. A change in utility value induced by an interventional treatment can be amalgamated with the duration of the treatment effect to provide the number of quality-adjusted life-years (QALYs) gained by a specific treatment (QALYs = [gain in utility value] x [duration of treatment effect]). Thus, this formula takes into account both the improvement in quality of life and the improvement in length of life gained by a treatment. The number of QALYs gained by a treatment can then be incorporated with medical costs (discounted for the time value of money) to arrive at a final common denominator of $/QALY (cost per QALY). The parameter $/QALY can be used to compare the cost-effectiveness of interventional treatments across diverse specialties in medicine. In essence, this methodology allows a measure of the cost-effectiveness of a treatment that incorporates the highest quality of scientific information, clinical efficacy, patient quality-of-life preferences, and realistic costs.

Entities:  

Mesh:

Year:  1999        PMID: 10537783     DOI: 10.1097/00055735-199906000-00012

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  17 in total

1.  The reproducibility of ophthalmic utility values.

Authors:  G C Brown; M M Brown; S Sharma; G Beauchamp; H Hollands
Journal:  Trans Am Ophthalmol Soc       Date:  2001

2.  A utility analysis correlation with visual acuity: methodologies and vision in the better and poorer eyes.

Authors:  M M Brown; G C Brown; S Sharma; A F Smith; J Landy
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

Review 3.  Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges.

Authors:  Jordana K Schmier; Carolyn K Hulme-Lowe
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

4.  Cost effectiveness of the type II Boston keratoprosthesis.

Authors:  J D Ament; T P Stryjewski; S Pujari; S Siddique; G N Papaliodis; J Chodosh; C H Dohlman
Journal:  Eye (Lond)       Date:  2010-12-24       Impact factor: 3.775

5.  Vision and quality-of-life.

Authors:  G C Brown
Journal:  Trans Am Ophthalmol Soc       Date:  1999

Review 6.  [Value-based medicine in ophthalmology].

Authors:  C Hirneiss; A S Neubauer; C Tribus; A Kampik
Journal:  Ophthalmologe       Date:  2006-06       Impact factor: 1.059

7.  Patient perceptions of quality-of-life associated with bilateral visual loss.

Authors:  G C Brown; M M Brown; S Sharma; H C Brown
Journal:  Int Ophthalmol       Date:  1998       Impact factor: 2.031

8.  Quality of life with macular degeneration: perceptions of patients, clinicians, and community members.

Authors:  J D Stein; M M Brown; G C Brown; H Hollands; S Sharma
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

9.  Utility values associated with blindness in an adult population.

Authors:  M M Brown; G C Brown; S Sharma; J Kistler; H Brown
Journal:  Br J Ophthalmol       Date:  2001-03       Impact factor: 4.638

Review 10.  The value of vision.

Authors:  Christine Knauer; Norbert Pfeiffer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-12-11       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.